A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinoma.
Zou X, Ding X, Feng ZK, Ouyang YF, Li HF, Wen K, Wang ZQ, Liu YP, Liu YL, Zhang WJ, Yang Q, Chen SY, Xie YL, Xie RQ, Lin C, Gu CM, Huang PY, Sun R, Hua YJ, You R, Chen MY.
Zou X, et al. Among authors: chen sy.
Cell Rep Med. 2024 Oct 15;5(10):101779. doi: 10.1016/j.xcrm.2024.101779.
Cell Rep Med. 2024.
PMID: 39413735
Clinical Trial.